PLX 51107
Alternative Names: PLX-51107Latest Information Update: 26 Feb 2024
At a glance
- Originator Plexxikon
- Developer Plexxikon; University of Texas M. D. Anderson Cancer Center
- Class Antineoplastics; Oxazoles; Pyrazoles; Pyridines; Small molecules
- Mechanism of Action BRD1 protein inhibitors; BRD2 protein inhibitors; BRD3 protein inhibitors; BRD4 protein inhibitors; Proto oncogene protein c-myc inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Acute myeloid leukaemia; Graft-versus-host disease; Myelodysplastic syndromes; Solid tumours
Most Recent Events
- 28 Sep 2023 Plexxikon completes a phase I/II clinical trials in Graft-versus-host disease (Second-line therapy or greater) in USA (PO) (NCT04910152)
- 07 Jul 2022 Discontinued - Phase-I for Acute myeloid leukaemia (Combination therapy, Second-line therapy or greater) in USA (PO)
- 07 Jul 2022 Discontinued - Phase-I for Acute myeloid leukaemia (Late-stage disease, Second-line therapy or greater) in USA (unspecified route)